Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...

Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Find insight on Roche, Novo Nordisk, Tricare and more in the latest Market Talks covering Health Care.

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss ...